RiMO-301

N/A

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameRiMO-301
Drug Alias NameRiMO-301
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionIndoleamine 2,3-dioxygenase inhibitors
TargetsIndoleamine 2,3-dioxygenase
Therapy Area/IndicationsHead and Neck NeoplasmsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesThe University Of Chicago
China Registration ClassN/A

Develop Information

Active CompaniesCoordination Pharmaceuticals Inc
Inactive CompaniesThe University Of Chicago
Active IndicationsHead and Neck Neoplasms
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A